Leonteq Securities AG Buys Shares of 132,512 Teladoc Health, Inc. $TDOC

Posted by Francis Steltz on May 22nd, 2026

Leonteq Securities AG bought a new stake in shares of Teladoc Health, Inc. (NYSE:TDOC – Free Report) in the 4th quarter, Holdings Channel reports. The institutional investor bought 132,512 shares of the health services provider’s stock, valued at approximately $928,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. IFP Advisors Inc raised its position in shares of Teladoc Health by 412.1% during the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 3,210 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after buying an additional 2,810 shares during the period. Aster Capital Management DIFC Ltd grew its holdings in shares of Teladoc Health by 101.1% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock valued at $37,000 after buying an additional 2,425 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Teladoc Health in the 4th quarter valued at $45,000. Finally, KBC Group NV grew its holdings in shares of Teladoc Health by 88.3% in the 4th quarter. KBC Group NV now owns 9,632 shares of the health services provider’s stock valued at $67,000 after buying an additional 4,516 shares during the period. Institutional investors own 76.82% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TDOC. Oppenheimer decreased their price target on shares of Teladoc Health from $12.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, March 3rd. Bank of America raised shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price target for the company in a report on Thursday, February 26th. Wells Fargo & Company decreased their price target on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, February 26th. Piper Sandler reissued an “overweight” rating and issued a $9.00 price target (down from $12.00) on shares of Teladoc Health in a report on Thursday, February 26th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Tuesday, March 10th. Five investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.53.

Check Out Our Latest Report on Teladoc Health

Teladoc Health Price Performance

Shares of NYSE TDOC opened at $6.55 on Friday. The firm has a market cap of $1.18 billion, a PE ratio of -6.75 and a beta of 2.08. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.75. Teladoc Health, Inc. has a 1-year low of $4.40 and a 1-year high of $9.77. The company has a fifty day moving average price of $5.83 and a 200 day moving average price of $6.25.

Teladoc Health (NYSE:TDOC – Get Free Report) last announced its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The company had revenue of $613.85 million during the quarter, compared to analyst estimates of $611.04 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.Teladoc Health’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.53) earnings per share. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. Research analysts predict that Teladoc Health, Inc. will post -0.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Charles Divita III sold 27,731 shares of the company’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $5.49, for a total value of $152,243.19. Following the completion of the transaction, the chief executive officer directly owned 364,784 shares of the company’s stock, valued at approximately $2,002,664.16. This represents a 7.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.70% of the company’s stock.

Teladoc Health Profile

(Free Report)

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.